| HOME >> BIOLOGY >> TECHNOLOGY |
-- Carbamazepine (36.5 percent seizure frequency reduction with Vimpat(R)
400 mg/day vs. 21.7 percent with placebo)
-- Lamotrigine (33.3 percent vs. 18.3 percent)
-- Levetiracetam (37.6 percent vs. 17.6 percent)
-- Valproate (45.3 percent vs. 21.3 percent)
-- Topiramate (41.4 percent vs. 28.5 percent)
-- Oxcarbazepine (27.2 percent vs. 12.5 percent)
Similar results were seen for responder rates (patients with 50 percent or greater reduction in seizure frequency):
-- Carbamazepine (37.4 percent responder rate with Vimpat(R) 400 mg/day
vs. 26.4 percent placebo)
-- Lamotrigine (34.2 percent vs. 19.0 percent)
-- Levetiracetam (43.4 percent vs. 19.4 percent)
-- Valproate (47.5 percent vs. 26.9 percent)
-- Topiramate (41.9 percent vs. 25.6 percent)
-- Oxcarbazepine (29.7 percent vs. 17.6 percent)
Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.246)
William Rosenfeld, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty, PhD
The Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, Missouri
Schwarz Biosciences Inc. (a member of the UCB Group), Raleigh, NC, USA
Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials
This pooled analysis clinical trial safety data showed Vimpat(R) to be generally well-tolerated, although 85 percent of trial participants were already taking two to three concomitant AEDs upon trial entry:
-- The most frequently reported individual treatment emergent adverse
events (TEAE) occurring in greater than or equal to 10 percent of the
Vimpat(
'/>"/>
| SOURCE UCB Copyright©2008 PR Newswire. All rights reserved |